

EnGeneIC announces appointment of Dr Mark Levitt to the Board of EnGeneIC

EnGeneIC is pleased to announce the immediate appointment of Dr Mark Levitt to the Board of EnGeneIC.

Dr Levitt's appointment is part of our process of board renewal which started with the appointment of Richard Woods as Acting Chairman last year. Mark brings experience across the whole range of EnGeneIC's activities with a background in clinical oncology development, business development and scientific and clinical evaluation. His career spans roles as an oncologist and researcher in the US and Israel, senior business executive with Teva Pharmaceuticals Industries Limited and now as a consultant and venture fund manager.

Mark knows EnGeneIC well and first met Himanshu and Jennifer in 2006 in his then role as Clinical Oncology Platform Leader at Teva. He has been an advisor to EnGeneIC since 2015 and is currently acting as the Medical Advisor for our clinical trial program.